A medicine for eczema: see if PF-08049820 helps adults with moderate to severe atopic dermatitis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase 2 trial investigates the safety and effectiveness of PF-08049820 in adults with atopic dermatitis. Participants will be randomized to receive either PF-08049820 or a matching placebo for 12 weeks, with visits to assess skin symptoms and overall health. The study includes two stages and collects blood and urine samples, with follow-up after the treatment period to monitor outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Participants must meet the following criteria:

1. Are 18 to 64 years of age
2. Have clinical diagnosis of AD for at least 6 months prior to Day 1 and have diagnosis of AD confirmed by photographs
3. Have moderate to severe AD as defined by the following at screening and baseline visits:

   * Affected body surface area (BSA) greater than or equal to 10% and up to 60%;
   * Validated Investigator's Global Assessment (vIGA) greater than or equal to 3;
   * Eczema Area and Severity Index (EASI) greater than or equal to 16;

   AND

   -Peak Pruritis Numeric Rating Scale (PP-NRS) greater than or equal to 4 at screening and a weekly average of greater than or equal to 4 at baseline visit
4. Do not have a suitable prescribed medicine for AD.
5. Body Mass Index (BMI) of 18 to 38 kg/m2 and a total body weight greater than 48 kg (106 lbs)

Exclusion Criteria:

Participants must not meet the following criteria:

1. Have an infection that requires treatment
2. Have other skin conditions other than AD
3. Have severe uncontrolled asthma
4. Regular use (more than 2 visits per week) of a tanning booth or phototherapy for AD within 4 weeks of the screening visit

Where it's running

• Mayo Clinic Hospital
  Phoenix, Arizona, United States Recruiting
• Mayo Clinic Specialty Building
  Phoenix, Arizona, United States Recruiting
• Mayo Clinic
  Scottsdale, Arizona, United States Recruiting
• Marvel Clinical Research
  Huntington Beach, California, United States Recruiting
• Northridge Clinical Trials
  Northridge, California, United States Recruiting
• Clinical Science Institute
  Santa Monica, California, United States Recruiting

+2 more sites. See ClinicalTrials.gov for the full list.

Study contacts

• Study coordinator: Pfizer CT.gov Call Center
• Email: ClinicalTrials.gov_Inquiries@pfizer.com
• Phone: 1-800-718-1021

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Camoteskimab in adults with moderate-to-severe atopic dermatitis

  This trial tests different doses of camoteskimab versus placebo to see if it helps adults with moderate-to-severe atopic dermatitis who have not fully responded to standard treatments.

  Recruiting at 31 sites Phase 2 Apollo Therapeutics Ltd · Birmingham, Alabama and 84 other locations · NCT07599813

• Soquelitinib for adults with moderate to severe atopic dermatitis

  This 12-week test gives adults with moderate to severe atopic dermatitis daily soquelitinib or a placebo to see if their skin and itch improve and to track side effects.

  Recruiting Phase 2 Corvus Pharmaceuticals, Inc. · South San Francisco, California · NCT07441395

• Testing a new hydrogel for treating mild to moderate eczema

  This study is testing a new hydrogel called zabalafin to see if it helps people with mild to moderate eczema feel better compared to a placebo.

  Recruiting at 12 sites Phase 2 Alphyn Biologics · Brookvale, New South Wales and 11 other locations · NCT06855745

• Cosmetic cream for treating very dry and irritated skin in children

  This study is testing a new cream for children with very dry and irritated skin to see if it helps improve their skin condition better than a fake cream.

  Recruiting NAOS Argentina S.A. · Ciudad Autónoma de Buenos Aire, Ciudad Autónoma de Buenos Aire and 2 other locations · NCT05575882

• Roflumilast Cream 0.3% for moderate to severe atopic dermatitis in children, adolescents, and adults

  A cream called roflumilast 0.3% is tested once daily to see if it helps people with moderate to severe atopic dermatitis, compared to a non-medicated cream, across ages 6 and up.

  Recruiting at 4 sites Phase 3 Arcutis Biotherapeutics, Inc. · Birmingham, Alabama and 3 other locations · NCT07916480

• Nocturnal ScratchSense ring: test of automatic scratch detection in adults with itchy skin

  This study tests whether the Replior ScratchSense ring can accurately detect and measure nighttime scratching in adults with itchy skin conditions.

  Recruiting Replior AB · Grenoble · NCT07909967

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.